In a landmark step towards advancing cancer care in the Middle East, Boston Oncology Arabia and Spimaco have signed a Memorandum of Understanding (MoU) to localise the production of advanced oral oncology treatments in the Kingdom.

Announced at the CPHI Middle East conference recently, this partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transformation.

Focused on the transfer of technology and knowledge, the collaboration will enable the parties to commercialise essential oral oncology medications domestically. The initiative not only improves access to life-saving treatments, but also strengthens the Kingdom’s industrial and healthcare infrastructure.

The partnership will prioritise the commercialisation of key oral oncology therapies over the next five years, driving significant benefits including job creation, the development of local expertise and production capacity, and equitable access to critical cancer treatments across Saudi Arabia and the broader MENA region.

This collaboration showcases the potential of bold strategic partnerships to unlock new opportunities to advance oncology care and address critical healthcare needs.